De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Genetic Signatures Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Neil Gunn

Algemeen directeur

AU$941.5k

Totale compensatie

Percentage CEO-salaris	15.2%
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.6yrs
Gemiddelde ambtstermijn bestuur	3yrs

Recente managementupdates

Recent updates

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

Jun 14

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Mar 08

A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)

Nov 14

Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected

Oct 10

One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates

Jun 29

Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Feb 28

AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results

Feb 25

What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?

Feb 07

What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?

Jan 17

Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth

Dec 27

Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business

Dec 06

Analyse CEO-vergoeding

Hoe is Neil Gunn's beloning veranderd ten opzichte van Genetic Signatures's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$941k	AU$143k	-AU$18m
Mar 31 2024	n/a	n/a	-AU$18m
Dec 31 2023	n/a	n/a	-AU$18m
Sep 30 2023	n/a	n/a	-AU$16m
Jun 30 2023	AU$190k	n/a	-AU$14m
Mar 31 2023	n/a	n/a	-AU$11m
Dec 31 2022	n/a	n/a	-AU$8m
Sep 30 2022	n/a	n/a	-AU$3m
Jun 30 2022	AU$169k	n/a	AU$3m
Mar 31 2022	n/a	n/a	AU$3m
Dec 31 2021	n/a	n/a	AU$2m
Sep 30 2021	n/a	n/a	AU$2m
Jun 30 2021	AU$19k	n/a	AU$2m

Compensatie versus markt: De totale vergoeding ($USD 649.73K ) Neil } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 312.49K ).

Compensatie versus inkomsten: De vergoeding van Neil is gestegen terwijl het bedrijf verliesgevend is.

CEO

Neil Gunn (63 yo)

less than a year

Tenure

AU$941,457

Compensatie

Dr. Neil Gunn serves as Independent Board Director of Rarecells Diagnostics SAS since September 2022. He serves as Independent Director at NeoGenomics, Inc. since June 26, 2023. He serves as Director at Ne...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Neil Gunn	Interim CEO & Non-Executive Director	less than a year	AU$941.46k	geen gegevens
Karl Pechmann	CFO, COO & Company Secretary	1.3yrs	AU$353.57k	geen gegevens
Michael Aicher	Executive Director of US Operations & Executive Director	10.8yrs	AU$182.63k	0.28% A$ 368.1k
Christopher Abbott	Founder & Chairman Emeritus	no data	geen gegevens	0% A$ 0
Rebecca Abbatantuono	Global Head of People & Culture	less than a year	geen gegevens	geen gegevens
Neralie Coulston	Global Head of Regulatory Affairs	1.9yrs	geen gegevens	geen gegevens
Jackson Jones	Chief Commercial Officer	1.9yrs	geen gegevens	geen gegevens

1.6yrs

Gemiddelde duur

Ervaren management: Het managementteam van GSS wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.6 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Neil Gunn	Interim CEO & Non-Executive Director	3.5yrs	AU$941.46k	geen gegevens
Michael Aicher	Executive Director of US Operations & Executive Director	10.8yrs	AU$182.63k	0.28% A$ 368.1k
Christopher Abbott	Founder & Chairman Emeritus	no data	geen gegevens	0% A$ 0
Jenny Harry	Non-Executive Director	no data	geen gegevens	geen gegevens
Caroline Waldron	Non-Executive Director	2.4yrs	AU$109.15k	0.0099% A$ 12.8k
Nickolaos Samaras	Independent Non-Executive Chairman	16.8yrs	AU$133.20k	1.1% A$ 1.4m
Anne Lockwood	Non-Executive Director	no data	geen gegevens	geen gegevens

3.0yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van GSS wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 3 jaar), wat duidt op een nieuw bestuur.

Genetic Signatures Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Genetic Signatures Limited Announces Changes to Board of Directors

Director recently bought AU$59k worth of stock

Genetic Signatures Limited, Annual General Meeting, Nov 29, 2023

Genetic Signatures Limited Appoints Karl Pechmann as Chief Financial Officer , Effective 26 June 2023

Less than half of directors are independent

Genetic Signatures Limited, Annual General Meeting, Nov 16, 2022

Recent updates

New minor risk - Market cap size

Consensus EPS estimates fall by 60%

Full year 2024 earnings: EPS misses analyst expectations

Genetic Signatures Limited Announces Changes to Board of Directors

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

New major risk - Shareholder dilution

Genetic Signatures Limited Announces That the US Food & Drug Administration Has Cleared the Company's Easyscreen™ Gastrointestinal Parasite Detection Kit and Gs1 Automated Workflow for Marketing and Sale in the US

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Director recently bought AU$59k worth of stock

New minor risk - Profitability

Consensus revenue estimates fall by 28%

Genetic Signatures Limited has completed a Follow-on Equity Offering in the amount of AUD 7.979326 million.

Genetic Signatures Limited has completed a Follow-on Equity Offering in the amount of AUD 7.97898 million.

Consensus revenue estimates decrease by 31%

New minor risk - Shareholder dilution

Genetic Signatures Limited has filed a Follow-on Equity Offering in the amount of AUD 7.97898 million.

Price target decreased by 20% to AU$0.90

Now 20% undervalued after recent price drop

A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)

Genetic Signatures Limited, Annual General Meeting, Nov 29, 2023

Now 21% undervalued after recent price drop

Full year 2023 earnings released: AU$0.098 loss per share (vs AU$0.021 profit in FY 2022)

New minor risk - Financial data availability

Genetic Signatures Limited Appoints Karl Pechmann as Chief Financial Officer , Effective 26 June 2023

Consensus EPS estimates fall by 37%

Price target increased by 8.0% to AU$0.95

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.033 profit in 1H 2022)

Less than half of directors are independent

Price target decreased to AU$0.90

Genetic Signatures Limited, Annual General Meeting, Nov 16, 2022

Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected

Full year 2022 earnings released: EPS: AU$0.021 (vs AU$0.012 in FY 2021)

Genetic Signatures Limited Announces Clinical Trial Recruitment Completed for US Enteric Kit

Genetic Signatures Limited Announces Appointment of Caroline Waldron as New Non-Executive Director

Price target decreased to AU$1.38

Less than half of directors are independent

First half 2022 earnings: EPS and revenues exceed analyst expectations

Genetic Signatures Limited Announces 3base® SARS-CoV-2 diagnostic kit registered by TGA for saliva samples

Full year 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target decreased to AU$2.20

One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates

Consensus revenue estimates fall to AU$28.0m

New 90-day low: AU$1.58

Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results

First half 2021 earnings released: EPS AU$0.032 (vs AU$0.021 loss in 1H 2020)

Revenue beats expectations, earnings disappoint

What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?

What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?

Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth

New 90-day low: AU$1.65

Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business

New 90-day low - AU$1.95

Full year earnings released - AU$0.016 loss per share

New 90-day high - AU$2.62

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd